Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
BioArctic reported that partner Eisai's preliminary global sales of Leqembi reached JPY 29.3 billion in the second quarter of 2026, generating a royalty of SEK 179 million for BioArctic. Excluding a one-time stockpiling effect from the prior year, royalty revenues grew approximately 43 percent year-over-year, indicating strong underlying demand for the Alzheimer's treatment.
Key figures
- Leqembi q2 2026 sales
- JPY 29.3 billion
- Bioarctic q2 2026 royalty
- SEK 179 million
- Organic royalty growth yoy
- 43%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.